Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 

      © 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

Donepezil taj Pharmaceuticals Ltd.

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Donepezil Manufacturers in India Suppliers Donepezil Exporters Distributors Donepezil api active pharmaceuticals ingredients Donepezil manufacturers Side Effects bulk drugs raw material Donepezil companies Side Effects Importers Donepezil Donepezil Exporters Donepezil exporters FDA Donepezil DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Donepezil manufacturing pharmaceutical drugs pharmaceutical intermediates Donepezil pharmaceutical chemicals pharmaceutical raw materials Donepezil active pharmaceutical ingredients Donepezil committee active pharmaceutical ingredients manufacturer Donepezil Active Pharmaceutical Ingredients manufacturer Donepezil exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Donepezil, Donepezil manufacturer India, Donepezil product, Donepezil products, Api preparation, Certificate of Analysis API manufacturer product, Donepezil anti ulcer product, Certificate of Origin COA Donepezil COS Donepezil, pharmaceutical generic, pharmaceutical drug, medical, Donepezil pharma healthcare, pharma patents, contract MSDS manufacturing Trader Donepezil pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Donepezil expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Donepezil DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Donepezil ingredients, api, HIV Donepezil, tablets, capsules, syrup & protein Donepezil powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Donepezil gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Donepezil WHO, UKMHRA Approval

   API >>>
   Pharmaceuticals API List
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us






HOME >> API >> API List1 >> Donepezil >> Pharmalogy

Donepezil CAS Number 120014-06-4

Donepezil CAS Number 120014-06-4

Clinical Trial Data

The effectiveness of Donepezil  as a treatment for Alzheimer's Disease is demonstrated by the results of randomized, double-blind, placebo-controlled clinical investigations in patients with mild to moderate Alzheimer's Disease, and in patients with severe Alzheimer's Disease.
Mild-Moderate Alzheimer's Disease

The effectiveness of Donepezil  as a treatment for mild to moderate Alzheimer's Disease is demonstrated by the results of two randomized, double-blind, placebo-controlled clinical investigations in patients with Alzheimer's Disease (diagnosed by NINCDS and DSM III-R criteria, Mini-Mental State Examination ≥ 10 and ≤ 26 and Clinical Dementia Rating of 1 or 2). The mean age of patients participating in Donepezil  trials was 73 years with a range of 50 to 94. Approximately 62% of patients were women and 38% were men. The racial distribution was white 95%, black 3% and other races 2%.

Study Outcome Measures: In each study, the effectiveness of treatment with Donepezil  was evaluated using a dual outcome assessment strategy.

The ability of Donepezil  to improve cognitive performance was assessed with the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog), a multi-item instrument that has been extensively validated in longitudinal cohorts of Alzheimer's Disease patients. The ADAS-cog examines selected aspects of cognitive performance including elements of memory, orientation, attention, reasoning, language and praxis. The ADAS-cog scoring range is from 0 to 70, with higher scores indicating greater cognitive impairment. Elderly normal adults may score as low as 0 or 1, but it is not unusual for non-demented adults to score slightly higher.

The patients recruited as participants in each study had mean scores on the Alzheimer's Disease Assessment Scale (ADAS-cog) of approximately 26 units, with a range from 4 to 61. Experience gained in longitudinal studies of ambulatory patients with mild to moderate Alzheimer's Disease suggest that they gain 6 to 12 units a year on the ADAS-cog. However, lesser degrees of change are seen in patients with very mild or very advanced disease because the ADAS-cog is not uniformly sensitive to change over the course of the disease. The annualized rate of decline in the placebo patients participating in Donepezil  trials was approximately 2 to 4 units per year.

The ability of Donepezil  to produce an overall clinical effect was assessed using a Clinician's Interview Based Impression of Change that required the use of caregiver information, the CIBIC plus. The CIBIC plus is not a single instrument and is not a standardized instrument like the ADAS-cog. Clinical trials for investigational drugs have used a variety of CIBIC formats, each different in terms of depth and structure.

As such, results from a CIBIC plus reflect clinical experience from the trial or trials in which it was used and cannot be compared directly with the results of CIBIC plus evaluations from other clinical trials. The CIBIC plus used in Donepezil  trials was a semi-structured instrument that was intended to examine four major areas of patient function: General, Cognitive, Behavioral and Activities of Daily Living. It represents the assessment of a skilled clinician based upon his/her observations at an interview with the patient, in combination with information supplied by a caregiver familiar with the behavior of the patient over the interval rated. The CIBIC plus is scored as a seven point categorical rating, ranging from a score of 1, indicating “markedly improved,” to a score of 4, indicating “no change” to a score of 7, indicating “markedly worse.” The CIBIC plus has not been systematically compared directly to assessments not using information from caregivers (CIBIC) or other global methods.

Information Associated with Product:
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj Pharmaceuticals API Logo


Api Manufacturing At Taj

Acamprosate Calcium

Clomipramine Hcl

Alendronate Sodium



Clopidogrel Bisulfate



Atomoxetine Hcl



Desmopressin Monoacetate


Divalproex Sodium


Dobutamine Hcl

Bupropion Hcl



Dothiepin Hcl






Escitalopram HBr





Cefuroxime Axetil



Fluticasone Propionate

Citalopram Hbr

Fluvoxamine Maleate

Fosphenytoin Sodium

Copyright © Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap


taj group logo
© 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.